Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity
after allogeneic stem-cell transplantation. Because of the small number of results from well …

This collaborative initiative aimed to provide recommendations on the use of polyclonal
antithymocyte globulin (ATG) or anti-T lymphocyte globulin (ATLG) for the prevention of graft …

Graft-versus-host disease (GVHD) is the most important complication of allogeneic
hematopoietic stem cell transplantation (alloHSCT). We performed a prospective …

PURPOSE The role of antithymocyte globulin (ATG) in preventing acute graft-versus-host
disease (aGVHD) after HLA-matched sibling donor transplantation (MSDT) is still …

Given that randomized studies testing the long-term impact of antithymocyte globulin (ATG)
dosing are scarce, we report the results of an extended follow-up from the original trial. In …

Background Previous trials testing prevention strategies for chronic graft versus host disease
(GVHD) have measured its cumulative incidence. In this trial of anti-thymocyte globulin, we …

Background: This retrospective study assessed the use and long-term outcome of allogeneic
hematopoietic stem cell transplantation (HSCT) in patients with severe autoimmune …

Post-transplantation cyclophosphamide (PTCy) has emerged as a promising graft-versus-
host-disease (GVHD) prophylaxis in the setting of allogeneic hematopoietic stem cell …

Patient-reported outcome (PRO) endpoints are increasingly considered for inclusion in
randomised controlled trials (RCTs) involving patients with haematological malignancies …

Purpose The survival rates of patients undergoing allogeneic hematopoietic stem cell
transplantation (HSCT) have improved. However, HSCT can induce significant long-term …